Total Payments
$19,520
2024 Payments
$1,244
Companies
22
Transactions
65
Medicare Patients
1,273
Medicare Billing
$210,920
Payment Breakdown by Category
Consulting$11,635 (59.6%)
Food & Beverage$4,557 (23.3%)
Other$1,879 (9.6%)
Travel$883.71 (4.5%)
Research$409.50 (2.1%)
Education$156.17 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,635 | 3 | 59.6% |
| Food and Beverage | $4,557 | 54 | 23.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,879 | 1 | 9.6% |
| Travel and Lodging | $883.71 | 2 | 4.5% |
| Unspecified | $409.50 | 1 | 2.1% |
| Education | $156.17 | 4 | 0.8% |
Payments by Type
General
$19,111
64 transactions
Research
$409.50
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,437 | 17 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $5,734 | 7 | $0 (2022) |
| Incyte Corporation | $1,879 | 1 | $0 (2017) |
| Alexion Pharmaceuticals, Inc. | $956.99 | 8 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $685.74 | 6 | $0 (2024) |
| Janssen Biotech, Inc. | $386.11 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $376.74 | 3 | $0 (2024) |
| Amgen Inc. | $285.73 | 3 | $0 (2018) |
| Celgene Corporation | $264.83 | 2 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $248.05 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,244 | 10 | AstraZeneca Pharmaceuticals LP ($255.17) |
| 2023 | $496.63 | 6 | Janssen Biotech, Inc. ($132.75) |
| 2022 | $5,876 | 9 | SERVIER PHARMACEUTICALS LLC ($5,734) |
| 2021 | $4,602 | 3 | Novartis Pharmaceuticals Corporation ($4,375) |
| 2020 | $2,822 | 5 | Novartis Pharmaceuticals Corporation ($2,500) |
| 2019 | $989.98 | 13 | Takeda Pharmaceuticals U.S.A., Inc. ($409.50) |
| 2018 | $881.84 | 12 | Novartis Pharmaceuticals Corporation ($287.11) |
| 2017 | $2,608 | 7 | Incyte Corporation ($1,879) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $158.53 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $95.38 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $128.78 | General |
| Category: Rare Disease | ||||||
| 08/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $123.85 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $121.90 | General |
| Category: Rare Disease | ||||||
| 05/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $145.03 | General |
| Category: Oncology | ||||||
| 05/09/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $108.47 | General |
| Category: Hematology | ||||||
| 05/02/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $106.73 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/26/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $120.17 | General |
| Category: Oncology | ||||||
| 05/16/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $132.75 | General |
| Category: Oncology | ||||||
| 03/16/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $55.68 | General |
| 03/15/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $119.85 | General |
| 02/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $34.03 | General |
| 01/19/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $121.57 | General |
| Category: Oncology | ||||||
| 01/11/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Education | In-kind items and services | $32.75 | General |
| Category: ONCOLOGY | ||||||
| 08/25/2022 | SERVIER PHARMACEUTICALS LLC | TIBSOVO (Drug) | Consulting Fee | Cash or cash equivalent | $4,760.00 | General |
| Category: Oncology | ||||||
| 08/23/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: Oncology | ||||||
| 08/05/2022 | SERVIER PHARMACEUTICALS LLC | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $40.81 | General |
| Category: Oncology | ||||||
| 08/05/2022 | SERVIER PHARMACEUTICALS LLC | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: Oncology | ||||||
| 08/05/2022 | SERVIER PHARMACEUTICALS LLC | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $9.86 | General |
| Category: Oncology | ||||||
| 08/05/2022 | SERVIER PHARMACEUTICALS LLC | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $9.86 | General |
| Category: Oncology | ||||||
| 08/04/2022 | SERVIER PHARMACEUTICALS LLC | TIBSOVO (Drug) | Travel and Lodging | In-kind items and services | $549.19 | General |
| Category: Oncology | ||||||
| 08/04/2022 | SERVIER PHARMACEUTICALS LLC | TIBSOVO (Drug) | Travel and Lodging | In-kind items and services | $334.52 | General |
| Category: Oncology | ||||||
| 02/10/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $121.90 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of Dexamethasone Plus IXAZOMIB MLN9708 or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain AL Amyloidosis | Takeda Pharmaceuticals U.S.A., Inc. | $409.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 356 | 800 | $232,558 | $58,657 |
| 2022 | 10 | 336 | 684 | $210,906 | $51,785 |
| 2021 | 12 | 345 | 775 | $218,465 | $60,576 |
| 2020 | 8 | 236 | 638 | $157,535 | $39,902 |
Total Patients
1,273
Total Services
2,897
Medicare Billing
$210,920
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 188 | $46,202 | $12,544 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 66 | 155 | $49,906 | $12,423 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 48 | 87 | $40,620 | $9,957 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 79 | 178 | $38,804 | $8,917 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $15,752 | $3,724 | 23.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 30 | $10,910 | $2,955 | 27.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 26 | 64 | $9,058 | $2,644 | 29.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 23 | $9,789 | $2,562 | 26.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 29 | 29 | $7,233 | $1,968 | 27.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 11 | 20 | $4,284 | $962.54 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 57 | 162 | $52,011 | $12,741 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 77 | 166 | $36,044 | $8,233 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 57 | $26,991 | $6,774 | 25.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 31 | 105 | $24,123 | $6,295 | 26.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 68 | $22,420 | $5,914 | 26.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 41 | 41 | $24,422 | $5,483 | 22.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $7,821 | $2,026 | 25.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 19 | 22 | $7,051 | $1,787 | 25.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 20 | 31 | $6,753 | $1,664 | 24.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 14 | 14 | $3,270 | $867.99 | 26.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 75 | 220 | $63,975 | $18,282 | 28.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 73 | 193 | $37,943 | $10,544 | 27.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 40 | 62 | $26,009 | $7,827 | 30.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 90 | $20,980 | $5,591 | 26.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 37 | 37 | $21,186 | $5,588 | 26.4% |
About Dr. Ronald Paquette, MD
Dr. Ronald Paquette, MD is a Hematology & Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992725576.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Paquette, MD has received a total of $19,520 in payments from pharmaceutical and medical device companies, with $1,244 received in 2024. These payments were reported across 65 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($11,635).
As a Medicare-enrolled provider, Paquette has provided services to 1,273 Medicare beneficiaries, totaling 2,897 services with total Medicare billing of $210,920. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Los Angeles, CA
- Active Since 07/19/2006
- Last Updated 05/30/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992725576
Products in Payments
- TIBSOVO (Drug) $5,746
- ABL002 (Drug) $2,500
- JAKAFI (Drug) $1,879
- Ninlaro (Drug) $409.50
- CALQUENCE (Drug) $376.74
- SOLIRIS (Drug) $359.61
- ADCETRIS (Biological) $275.00
- DARZALEX (Biological) $253.36
- ULTOMIRIS (Biological) $250.68
- Imbruvica (Drug) $248.05
- KYMRIAH (Biological) $188.44
- Blincyto (Biological) $169.76
- XPOVIO (Drug) $158.53
- ICLUSIG (Drug) $156.60
- IMBRUVICA (Drug) $132.75
- VYXEOS (Drug) $125.00
- GAZYVA (Biological) $124.96
- ONUREG (Drug) $121.90
- XOSPATA (Drug) $118.90
- REBLOZYL (Biological) $108.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Angeles
Dennis Slamon, Md, MD
Hematology & Oncology — Payments: $4.3M
Hematology & Oncology $4.3M
George Yaghmour
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Robert Vescio, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Kevin Kelly, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
David Berz, Md, Phd, Mph, MD, PHD, MPH
Hematology & Oncology — Payments: $613,380
Hematology & Oncology $613,380
Raghuveer Ranganathan, M.d, M.D
Hematology & Oncology — Payments: $472,334
Hematology & Oncology $472,334